Core Laboratories director awarded and vests shares

Core Laboratories Inc. director Robert F. Martinovich reported equity-based compensation activity.

Rhea-AI Filing Summary

Core Laboratories Inc. director Robert F. Martinovich reported equity-based compensation activity. He received a grant of 7,895 Restricted Shares that will vest after a one-year vesting period ending on April 1, 2027, subject to the terms of issuance and any deferral election.

Separately, 8,069 Restricted Shares vested at the end of a prior one-year vesting period on April 1, 2026 and were exercised into 8,069 shares of Common Stock, which he now holds directly. The filing shows only awards and an option-style conversion of restricted equity into common stock, with no open-market purchases or sales.

Insider Trade Summary

8,069 shares exercised/converted

Exercise 3 txns

Insider MARTINOVICH ROBERT F

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Shares	7,895	$0.00	$0.00
Exercise	Restricted Shares	8,069	$0.00	$0.00
Exercise	Common Stock	8,069	$0.00	$0.00

Holdings After Transaction: Restricted Shares — 7,895 contracts (Direct); Common Stock — 8,069 shares (Direct)

Footnotes (2)

1. F1. The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027, subject to the terms of issuance. Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2, and the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board.
2. F2. The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2026.

Key Figures

Restricted Shares granted: 7,895 shares New grant vesting date: April 1, 2027 Restricted Shares vested: 8,069 shares +3 more

6 metrics

Restricted Shares granted 7,895 shares Equity award granted on April 1, 2026

New grant vesting date April 1, 2027 End of one-year vesting period for 7,895 Restricted Shares

Restricted Shares vested 8,069 shares Previously granted Restricted Shares vesting period ending April 1, 2026

Common Stock after conversion 8,069 shares Common Stock held directly following derivative exercise

Exercise/Conversion price $0.00 per share Reported transaction price for Restricted Shares exercise

Derivative exercises in filing 1 exercise, 8,069 shares transactionSummary exerciseCount and exerciseShares

Key Terms

Restricted Shares, derivative security, Treasury Regulation 1.409A-2, deferral election, +1 more

5 terms

Restricted Shares financial

"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period"

Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

Treasury Regulation 1.409A-2 financial

"subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2"

deferral election financial

"Such shares remain subject to a deferral election by the Reporting Person"

vesting period financial

"will vest, without performance criteria, at the end of a one-year vesting period"

A vesting period is the set amount of time someone must wait before they fully own granted shares, stock options, or other equity tied to their work or an agreement; ownership increases gradually or in steps during that time. Investors care because vesting determines when insiders or employees can sell shares, which affects future supply of stock, company incentives and executive retention—think of it like unlocking ownership over installments rather than receiving it all at once.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Core Laboratories (CLB) director Robert F. Martinovich report in this Form 4?

Robert F. Martinovich reported equity compensation activity, not market trades. He received a grant of 7,895 Restricted Shares and saw 8,069 previously granted Restricted Shares vest and convert into 8,069 shares of Common Stock, which he now holds directly.

How many Restricted Shares were granted to the Core Laboratories (CLB) director?

He was granted 7,895 Restricted Shares. These shares are subject to a one-year vesting period ending on April 1, 2027 and remain subject to the terms of issuance, including a possible deferral election affecting when vested shares are delivered.

When do the newly granted Restricted Shares for CLB’s director vest?

The newly granted 7,895 Restricted Shares will vest at the end of a one-year vesting period on April 1, 2027. Vesting is subject to the terms of issuance and any deferral election under Treasury Regulation 1.409A-2 chosen by the reporting person.

What happened to the 8,069 Restricted Shares reported by the Core Laboratories (CLB) director?

8,069 previously awarded Restricted Shares completed their one-year vesting period ending April 1, 2026. Upon vesting, they were exercised or converted into 8,069 shares of Core Laboratories Common Stock, which are now held directly by the director according to the filing.

Does this Core Laboratories (CLB) Form 4 show any open-market stock purchases or sales?

No, the Form 4 reports only equity award grants and the vesting and conversion of Restricted Shares into Common Stock. The transactions use codes A and M, indicating awards and derivative exercises, with no open-market buy or sell transactions disclosed in this filing.

How many Core Laboratories (CLB) Common Stock shares does the director hold from these transactions?

Following the reported conversion, the director holds 8,069 shares of Core Laboratories Common Stock directly from the vested Restricted Shares. This figure reflects the result of the 8,069-share derivative exercise disclosed, not his total overall share ownership position with the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/07/2026 - 07:43 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MARTINOVICH ROBERT F

(Last) (First) (Middle)

6316 WINDFERN RD

(Street)

HOUSTON TEXAS 77040

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Core Laboratories Inc. /DE/ [ CLB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		M		8,069	A	$0	8,069	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Shares	$0	04/01/2026		A		7,895		(1)	(1)	Common Stock	7,895	$0	7,895	D
Restricted Shares	$0	04/01/2026		M			8,069	(2)	(2)	Common Stock	8,069	$0	0	D

Explanation of Responses:

1. The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027, subject to the terms of issuance. Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2, and the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board.

2. The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2026.

	/s/ Mark Tattoli, Attorney-in-Fact	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)